Literature DB >> 29736215

Localization of center of intramuscular nerve dense regions in adult anterior brachial muscles: a guide for botulinum toxin A injection to treat muscle spasticity.

Shaohua Tang1, Ming Xiaoming Zhang2, Shengbo Yang1.   

Abstract

This study aimed to identify the location and depth of the center of intramuscular nerves dense regions (CINDRs) in anterior brachial muscles. Twelve adult cadavers were used. One side anterior brachial muscles were isolated and subjected to Sihler's staining to show intramuscular nerve dense regions. Then the data was used to localize CINDRs in situ on the same muscles of the contralateral side. The localization method involved dissection and exposure of CINDRs, barium sulfate labeling, body surface reference line design, spiral computed tomography scan, three-dimensional image reconstruction, and Syngo system measurements. The number of CINDRs in coracobrachialis, biceps brachii and brachialis muscle were 3, 2 and 2, respectively. The body surface coordinates for the three CINDRs in coracobrachialis muscle were at 24.22%, 18.89% and 8.15% on the horizontal reference line and 21.37%, 31.78% and 30.07% on the longitudinal reference line. For biceps brachii muscle, they were at 49.68% and 40.28% on the horizontal reference line and 56.60% and 67.63% on the longitudinal reference line. For brachialis muscle, they were at 48.34% and 52.45% on the horizontal reference line and 71.30% and 81.62% on the longitudinal reference line. On cross-sectional planes, the depths of these CINDRs were at 22.81%, 26.76% and 27.99% (coracobrachialis); 14.79% and 17.45% (biceps); 34.03% and 30.26% (brachialis) of section diameters through CINDRs. These results may help to guide the injection of botulinum toxin A for the treatment of spasticity in the anterior brachial muscles and improve treatment efficacy and efficiency.

Entities:  

Keywords:  Anterior brachial muscles; intramuscular nerve dense regions; muscle spasticity; spiral computed tomography; target localization

Year:  2018        PMID: 29736215      PMCID: PMC5934581     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  21 in total

1.  [Therapeutic outcome of onabotulinum toxin type A in patients with upper limb spasticity].

Authors:  Yoshihiko Horimoto; Aki Inagaki; Mika Yoshikawa; Kumi Kanbe; Hajime Tanaka; Reika Ando; Hiroaki Hibino; Toshihisa Tajima; Kazutoshi Fukagawa; Hidehiro Kabasawa
Journal:  Rinsho Shinkeigaku       Date:  2015-07-07

2.  Anatomic localization of motor entry points and intramuscular nerve endings in the hamstring muscles.

Authors:  X C An; J H Lee; S Im; M S Lee; K Hwang; H W Kim; Seung-Ho Han
Journal:  Surg Radiol Anat       Date:  2010-01-10       Impact factor: 1.246

3.  Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity.

Authors:  M A Keenan; E S Tomas; L Stone; L M Gerstén
Journal:  J Hand Surg Am       Date:  1990-03       Impact factor: 2.230

4.  Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis.

Authors:  Alessandro Picelli; Gabriella Vallies; Elena Chemello; Paola Castellazzi; Annalisa Brugnera; Marialuisa Gandolfi; Alessio Baricich; Carlo Cisari; Andrea Santamato; Leopold Saltuari; Andreas Waldner; Nicola Smania
Journal:  J Neurol Sci       Date:  2017-07-20       Impact factor: 3.181

5.  Ultrasound guided alcohol neurolysis of musculocutaneous nerve to relieve elbow spasticity in hemiparetic stroke patients.

Authors:  Dong Gyu Lee; Sung Ho Jang
Journal:  NeuroRehabilitation       Date:  2012       Impact factor: 2.138

Review 6.  Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Yan Dong; Tao Wu; Xiaohua Hu; Tong Wang
Journal:  Eur J Phys Rehabil Med       Date:  2016-11-11       Impact factor: 2.874

7.  Neurolysis of the musculocutaneous nerve with alcohol to treat poststroke elbow flexor spasticity.

Authors:  K H Kong; K S Chua
Journal:  Arch Phys Med Rehabil       Date:  1999-10       Impact factor: 3.966

8.  [The application of high-frequency and iTBS transcranial magnetic stimulation for the treatment of spasticity in the patients presenting with secondary progressive multiple sclerosis].

Authors:  J E Korzhova; A V Chervyakov; A G Poydasheva; I A Kochergin; A V Peresedova; M N Zakharova; N A Suponeva; L A Chernikova; M A Piradov
Journal:  Vopr Kurortol Fizioter Lech Fiz Kult       Date:  2016

9.  Musculocutaneous neurectomy for spastic elbow flexion in non-functional upper extremities in adults.

Authors:  D E Garland; R Thompson; R L Waters
Journal:  J Bone Joint Surg Am       Date:  1980-01       Impact factor: 5.284

10.  Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial.

Authors:  Hyung Seok Nam; Yoon Ghil Park; Nam-Jong Paik; Byung-Mo Oh; Min Ho Chun; Hea-Eun Yang; Dae Hyun Kim; Youbin Yi; Han Gil Seo; Kwang Dong Kim; Min Cheol Chang; Jae Hak Ryu; Shi-Uk Lee
Journal:  J Neurol Sci       Date:  2015-07-21       Impact factor: 3.181

View more
  3 in total

1.  Localization of the Center of the Intramuscular Nerve Dense Region of the Suboccipital Muscles: An Anatomical Study.

Authors:  Jie Wang; Yanrong Li; Meng Wang; Shengbo Yang
Journal:  Front Neurol       Date:  2022-04-06       Impact factor: 4.003

2.  Anatomical analysis of antebrachial cutaneous nerve distribution pattern and its clinical implications for sensory reconstruction.

Authors:  Hui Li; Weiwei Zhu; Shouwen Wu; Zairong Wei; Shengbo Yang
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

3.  Localization of nerve entry points and the center of intramuscular nerve-dense regions in the adult pectoralis major and pectoralis minor and its significance in blocking muscle spasticity.

Authors:  Yanrong Li; Meng Wang; Shaohua Tang; Xiankun Zhu; Shengbo Yang
Journal:  J Anat       Date:  2021-06-27       Impact factor: 2.610

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.